Amylyx Pharmaceuticals Total Current Liabilities

Amylyx Pharmaceuticals (AMLX) currently reports a total current liabilities of $21M as of June 2026. That compares with $21M in the prior-year period — down 1.3% year over year. Use the charts on this page to explore Amylyx Pharmaceuticals's total current liabilities history and peer comparisons.

Amylyx Pharmaceuticals's total current liabilities decreased from $21M to $21M — a 1.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Amylyx Pharmaceuticals reported $21M in total current liabilities as of June 2026. That compares with $21M in the prior-year period — down 1.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $21M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Amylyx Pharmaceuticals, and consider following AMLX for alerts when major investors trade the stock.